Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy
NCT ID: NCT00895440
Last Updated: 2013-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
139 participants
OBSERVATIONAL
2009-07-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This colour indicator, a cobalt-II-salt, is applied in the form of a plaster to the area of skin on the patient's foot to be examined. In healthy subjects, the moisture (sweat) on the foot changes the colour of the Neuropad plaster from blue to pink normally within minutes. However, if the colour does not change completely or very slowly, this indicates initial nerve damage. This test is, as yet, the only one that examines changes in moistness of the foot. The speed and scale of the colour change of the Neuropad plaster can then be assessed as indicators of sudomotor function and thus as indicators of diabetic neuropathy as well. Although the test has been done in patients with diabetic neuropathy it has not been used as a discriminator in painless and painful neuropathy, or in patients with Charcot neuroarthropathy.
In this study we aim to assess the presence of sudomotor dysfunction in patients with painful and painless neuropathy and patients with Charcot foot.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Diabetic patients without neuropathy
No interventions assigned to this group
2
Diabetic patients with painless neuropathy
No interventions assigned to this group
3
Diabetic patients with painful neuropathy
No interventions assigned to this group
4
Diabetic patients with Charcot neuroarthropathy
No interventions assigned to this group
5
Control non-diabetic subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18-70 years
3. Presence of painless neuropathy
4. Presence of painful neuropathy
5. Presence of Charcot foot
Exclusion Criteria
2. Peripheral vascular disease (defined as the absence of two or more foot pulses and an ankle brachial index of \< 0.8)
3. Renal failure (serum creatinine \> 130 micromol/l)
4. Foot ulceration or cellulitis or osteomyelitis
5. Patients taking drugs that affect sweating (corticosteroids, antihistamines, psychoactive drugs)
6. Chronic alcohol abuse
7. B12 deficiency (presence of anaemia, raised mean corpuscular volume, past history of abnormal B12 levels, treatment with B12)
8. Patients with any skin conditions affecting their feet(neurodermatitis, psoriasis, scleroderma, Raynaud syndrome, hyperhydrosis, acrocyanosis)
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tameside Hospital NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Edward Jude
Consultant Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward Jude, MD, MRCP
Role: PRINCIPAL_INVESTIGATOR
Tameside General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tameside General Hospital
Ashton-under-Lyne, Lancashire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Papanas N, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D, Maltezos E. A comparison of the new indicator test for sudomotor function (Neuropad) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2008 Feb;116(2):135-8. doi: 10.1055/s-2007-984455. Epub 2007 Dec 20.
Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, Monastiriotis C, Maltezos E. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):195-8. doi: 10.1055/s-2005-837735.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Neuropad01
Identifier Type: -
Identifier Source: org_study_id